b.next公司的合成细胞研究团队在应对供应链危机的过程中，建立了一座专门生产合成细胞核心材料的工厂。1该公司从2023年开始从事合成细胞传感器的相关合作开发，1但随后面临严峻的原料短缺问题——Roche在2023年停止供应tRNA，Sigma公司也随之中断了相关试剂供应。1
为解决这一困境，b.next团队耗时两年多开发了开源PURE系统，克服了材料许可限制和试剂供应中断的障碍。12024年中期，该公司通过Nucleus平台首次分享了PURE协议和质粒，1到2025年中期完成了所有PURE组分的开源协议和规格开发。1随后在2025年末至2026年初，该公司在旧金山建立并运营了这座制造工厂。1
截至目前，b.next已向全球约20个实验室供应了超过百套Cytosol试剂盒。1
b.next, a company conducting academic research in synthetic cell development, established a manufacturing facility to produce Cytosol, a core material used in synthetic cells, after encountering critical supply chain disruptions.1 The company faced constraints when Roche halted tRNA supplies in 2023, followed by Sigma's discontinuation of related reagents.1
To address these challenges, b.next undertook more than two years of development work on an open-source PURE system, overcoming material licensing restrictions and reagent supply interruptions.1 Beginning in mid-2024, the company shared PURE protocols and plasmids through its Nucleus platform, and by mid-2025 had completed open-source protocols and specifications for all PURE components.1 The facility in San Francisco became operational in late 2025 to early 2026.1
Since establishing operations, b.next has supplied over one hundred Cytosol reagent kits to approximately twenty laboratories worldwide over the past six months.1
评论
还没有评论，欢迎留下第一条。